_____________ __________ _____________
The following discussion includes references to US prescription and US market share data for key products. The source of this data is IMS Health, December 2007.
ADDERALL XR - ADHD
As a result of the launch of VYVANSE in July 2007 ADDERALL XR's average share of the US ADHD market for 2007 fell to 25.5% (2006: 26.1%). US prescriptions for ADDERALL XR for the year to December 31, 2007 increased by 3% compared to the same period in 2006 due to a 6% growth in the US ADHD market offset by the 0.6% fall in average market share.
Sales of ADDERALL XR for the year to December 31, 2007 were US$1,030.9 million, an increase of 19% compared to the same period in 2006 (2006: US$863.6 million). Product sales growth was higher than prescription growth due primarily to price increases in January and October 2007.
As previously disclosed, the United States Federal Trade Commission ("FTC") informed Shire on October 3, 2006 that it was reviewing the ADDERALL XR patent litigation settlement agreement between Shire and Barr Laboratories, Inc. ("Barr"). On June 22, 2007, the Group received a civil investigative demand requesting that it provides information to the FTC relating to its settlement with Barr and its earlier settlement with Impax Laboratories, Inc. The Group is cooperating fully with this investigation and believes that the settlements are in compliance with all applicable laws.
Patent litigation proceedings relating to ADDERALL XR are on-going. Further information can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2007.
VYVANSE - ADHD
VYVANSE was launched in the US market in July 2007 and at December 31,
2007 its market share had reached 5.2% (average annual market share 1.8%).
Product sales of US$76.5 million for the year to December 31,
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved